<p>In a study led by investigators from <a href="https://www.massgeneralbrigham.org/" target=" blank">Mass General Brigham</a>, <a href="https://wyss.harvard.edu/" target=" blank">the Wyss Institute for Biologically Inspired Engineering at Harvard University</a> and <a href="https://www.dana-farber.org/" target=" blank">Dana-Farber Cancer Institute</a>, in collaboration with researchers from across the country and beyond the U.S., researchers developed a low-cost, ultrasensitive blood test to detect minute levels of a cancer biomarker that is highly specific to multiple common cancers. Each test can be performed with merely half a drop of blood (25 microliters). The tool showed promise for early cancer detection and disease monitoring, and could potentially be used in conjunction with other tools for detection, risk stratification and treatment. Results are published in <a href=&quo
Pan-Cancer Biomarker Detected by Ultrasensitive Blood Test
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Dana-Farber researchers present key studies at ASCO annual meeting 20 May
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Repertoire Immune Medicines and Dana-Farber Cancer Institute Collaborate to Identify Novel Antigen Targets Within HPV+ Head and Neck Cancers
February 11, 2021 GMT
Anthony Coyle, Ph.D., President, Research and Development, Repertoire Immune Medicines (Photo: Business Wire)
CAMBRIDGE, Mass. (BUSINESS WIRE) Feb 11, 2021
Repertoire Immune Medicines, a clinical-stage biotech company creating a new category of immune therapies for cancer, autoimmunity and infectious disease, today announced a research collaboration with Dana-Farber Cancer Institute to advance discovery and clinical development in human papillomavirus-positive (HPV+) oropharyngeal (head and neck) cancers. Through this collaboration, Dana-Farber and Repertoire aim to identify novel tumor antigen targets relevant to HPV+ head and neck tumors that will be used to inform the development of novel therapeutic candidates.